LY03005 is an investigational drug.
There have been 8 clinical trials for LY03005.
The most recent clinical trial was a Phase 3 trial, which was initiated on December 5th 2018.
The most common disease conditions in clinical trials are Depressive Disorder, Major, Depressive Disorder, and Depression. The leading clinical trial sponsors are Luye Pharma Group Ltd., Shandong Luye Pharmaceutical Co., Ltd., and [disabled in preview].
There are four US patents protecting this investigational drug and fifty-one international patents.